Medically reviewed by Sohaib Imtiaz, MD Semaglutide is an injectable medication available as Ozempic and Rybelsus to treat ...

which involved around 800 patients treated with semaglutide or placebo on top of standard care and followed for 72 weeks. MASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

The treated obese mice experienced significant weight loss (primarily from fat) along with improved glucose and insulin tolerance compared to the control group. These effects were comparable to those ...

Studies show promising results for semaglutide as a potential treatment for alcohol use disorder. Semaglutide, a GLP-1 drug, was initially used for type 2 diabetes treatment and weight loss.

💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular events by 14% in people with type 2 diabetes and heart or kidney disease. ️ The ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

In India, there were 32 centres and 788 people enrolled. Semaglutide was initially approved in June 2021 for chronic weight management in those with obesity or overweight and at least one weight ...